Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
1(6%)
Results Posted
57%(8 trials)

Phase Distribution

Ph phase_3
8
47%
Ph phase_1
2
12%
Ph phase_2
7
41%

Phase Distribution

2

Early Stage

7

Mid Stage

8

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
7(41.2%)
Phase 3Large-scale testing
8(47.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

17

all time

Status Distribution
Active(1)
Completed(14)
Terminated(2)

Detailed Status

Completed14
Withdrawn2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (11.8%)
Phase 27 (41.2%)
Phase 38 (47.1%)

Trials by Status

withdrawn212%
completed1482%
active_not_recruiting16%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT03941236Phase 3

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Active Not Recruiting
NCT06588504Phase 1

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Completed
NCT05378672Phase 3

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Completed
NCT04172441Phase 2

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Completed
NCT05454709Phase 2

A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System

Withdrawn
NCT03777176Phase 3

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Completed
NCT04824872Phase 2

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Withdrawn
NCT03895697Phase 3

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Completed
NCT04836273Phase 2

Treatment of Post-bariatric Hypoglycaemia

Completed
NCT04764968Phase 2

Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Completed
NCT03667053Phase 3

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Completed
NCT03378635Phase 3

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Completed
NCT03688711Phase 3

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Completed
NCT03216226Phase 3

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Completed
NCT03735225Phase 1

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Completed
NCT04449692Phase 2

Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

Completed
NCT03840278Phase 2

The Bihormonal iLet Bionic Pancreas Feasibility Study

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17